USP18 and hyperinsulinemic hypoglycemia, familial, 4: JAK inhibitors such as ruxolitinib have been reported in isolated cases, with one Saudi infant with USP18 deficiency surviving beyond infancy after treatment [15], in contrast to the otherwise universally fatal course [4,10].